Pacific Edge

4 articles about Pacific Edge

• Pacific Edge Diagnostics Notified of CMS LCD Coverage for Cxbladder®Milestone achievement for Pacific Edge Diagnostics facilitates reimbursement for Cxbladder® testing for Medicare patients.

  10/12/2020

  Bladder cancer diagnostics provider, Pacific Edge Diagnostics, has been notified by Novitas1 that the LCD: Biomarkers for Oncology (L35396) provides coverage for Cxbladder (0012M and 0013M) for tests performed on or after July 1, 2020 that are medically necessary. This LCD coverage enables national reimbursement for Cxbladder tests performed among the approximately 62 million people who have Medicare coverage with the Centers for Medicare

• Cxbladder™ Monitor Demonstrates Clinical Utility In Patients Being Monitored For Recurrent Bladder Cancer (UC)

  5/24/2018

  The addition of Cxbladder Monitor for bladder cancer surveillance has been shown to enable physicians to reduce the overall number of diagnostic tests being ordered, potentially reducing the total cost of monitoring and reducing complications related to unnecessary tests.

• Pacific Edge Release: Cxbladder Monitor Significantly Outperforms All Compared FDA Approved Urine Tests For Bladder Cancer; Enhancing The Standard Of Care For Bladder Cancer Patients

  4/12/2017

• Pacific Edge Launches Cxbladder Monitor In The United States

  12/13/2016